In addition, genetic partial loss of SGLT1 function is not only associated with lower PPG, but also with reduced rates of T2D, obesity, congestive heart failure and mortality in affected individuals, suggesting that partial pharmacologic inhibition of intestinal SGLT1 by sotagliflozin may provide similar beneficial effects (35). This evidence concerns the gene SLC5A1 and obesity disorder.